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Activation of CD40 on dendritic cells increases cross-
presentation of tumor antigens and as a result the num-
ber of activated tumor directed T effector cells. CD40
agonists have been shown to generate powerful systemic
anti-tumor responses when administered in situ.
The pre-clinical proof of concept data has been gener-
ated mainly using an hCD40 transgenic mouse
(hCD40tg) strain. Anti-tumor effects has been demon-
strated in multiple syngeneic tumor models including
bladder tumor (MB49), melanoma (B16) and lymphoma
(A20) models. The anti-tumor effects has been shown to
induce long term, T cell dependent, tumor immunity.
As expected, the anti-tumor effects depends on the
immune status of the tumors as evaluated by immuno-
histochemistry and flow cytometry.
Since CD40 agonistic antibodies mainly exert their
effects upstream of the checkpoint inhibitors they have
the potential to be ideal candidates for combination
regimens including e.g. PD-1 antagonists and OX40
antibodies. Combining ADC-1013 with antibodies
against these targets has been shown to improve the
anti-tumor effects in B16.F10 melanoma.
Toxicology studies were performed in cynomolgus
monkeys using subcutaneous or intravenous administra-
tion. Doses of 1 to 10 mg/kg were evaluated in both stu-
dies. ADC-1013 was well tolerated at all dose levels and
no major safety concerns were identified. Receptor
saturation of approximately 95% was achieved and phar-
macodynamic activity, notably B-cell depletion, was
observed at all dose levels.
In cynomolgus monkey, serum concentrations of
ADC-1013 declined in a multi-phasic manner following
a single intravenous dose. The mean terminal half-life
was approximately 30 hours. Following subcutaneous
administration the mean elimination half-life was found
to be between 0.6 and 3.2 days. The clearance (CL_F)
decreased and the half-life increased with increasing
dose indicating target-mediated clearance.
Alligator Bioscience has recently started dosing of the
first patients in a clinical trial of the CD40 agonistic anti-
body ADC-1013. The study is a first-in-human, multicen-
ter, open-label, multiple ascending dose Phase I study in
patients with advanced solid tumors to determine the
safety, pharmacokinetics and pharmacodynamics of intra-
tumorally administered ADC-1013.
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